Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Cash (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Change in Cash for 3 consecutive years, with -$15.6 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 354.65% to -$15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.8 million through Dec 2025, down 166.68% year-over-year, with the annual reading at -$12.8 million for FY2025, 166.68% down from the prior year.
  • Change in Cash hit -$15.6 million in Q4 2025 for Compass Therapeutics, down from $23.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $23.4 million in Q3 2025 to a low of -$18.2 million in Q2 2025.
  • Historically, Change in Cash has averaged -$358583.3 across 3 years, with a median of -$3.4 million in 2024.
  • Biggest five-year swings in Change in Cash: soared 198.64% in 2024 and later crashed 354.65% in 2025.
  • Year by year, Change in Cash stood at -$6.2 million in 2023, then surged by 198.64% to $6.1 million in 2024, then crashed by 354.65% to -$15.6 million in 2025.
  • Business Quant data shows Change in Cash for CMPX at -$15.6 million in Q4 2025, $23.4 million in Q3 2025, and -$18.2 million in Q2 2025.